Peginterferon beta - Allozyne

Drug Profile

Peginterferon beta - Allozyne

Alternative Names: AZ 01; PEG-IFN-beta - Allozyne

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allozyne
  • Class Interferons; Proteins
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 15 Apr 2016 No recent reports on development identified - Phase-I for Multiple sclerosis (In volunteers) in USA (Parenteral)
  • 18 Oct 2011 Interim adverse events, pharmacokinetics and pharmacodynamics data from a phase Ib trial in volunteers released by Allozyne
  • 11 Jan 2011 Topline adverse events and pharmacodynamics data from a phase I trial in Multiple sclerosis released by Allozyne
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top